leadf
logo-loader
viewSUDA Pharmaceuticals Ltd

Suda Pharmaceuticals' Dr Michael Baker hails regulatory approval for lead product ZolpiMist

Dr Michael Baker, CEO of SUDA Pharmaceuticals Ltd (ASX:SUD), speaks to Proactive's Andrew Scott soon after announcing they've received Therapeutics Goods Administration (TGA) approval for their lead product ZolpiMist for the treatment of short-term insomnia in adults. Baker says it's a significant milestone for the company and is the first product they've had approved by a regulator. ''Backing that up we've got a number of other products, one I'm particularly excited about, which we're developing for the treatment of cancer as well as one for migraine and also a couple of products in the medical cannabis space''.

Quick facts: SUDA Pharmaceuticals Ltd

Price: 0.042 AUD

ASX:SUD
Market: ASX
Market Cap: $12.89 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of SUDA Pharmaceuticals Ltd named herein, including the promotion by the Company of SUDA Pharmaceuticals Ltd in any Content on the Site, the...

FOR OUR FULL DISCLAIMER CLICK HERE

ImmuPharma’s partner Avion set to meet FDA in December to discuss Phase 3...

Dr Tim Franklin, Chief Operating Officer of ImmuPharma PLC (LON:IMM) joins Proactive London's Katie Pilbeam to discuss ImmuPharma's announcement that The US Food & Drug Administration (“FDA”) has confirmed 4th December 2020 will be the date for the Type ‘A’ Meeting Request, with Avion...

1 hour, 14 minutes ago

2 min read